Condensed Consolidated Statements of Changes in Stockholders’ Deficit - USD ($) shares in Thousands, $ in Thousands	Total	Issuance of new common stock in connection with emergence	Issuance of new common stock under the Equity Rights Offering	Issuance of new common stock for the Equity Rights Offering backstop commitment	Issuance of new common stock for Bitmain obligation	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, Adjusted Balance	Common Stock	Common Stock Issuance of new common stock in connection with emergence	Common Stock Issuance of new common stock under the Equity Rights Offering	Common Stock Issuance of new common stock for the Equity Rights Offering backstop commitment	Common Stock Issuance of new common stock for Bitmain obligation	Common Stock Cumulative Effect, Period of Adoption, Adjusted Balance	Additional Paid-In Capital	Additional Paid-In Capital Issuance of new common stock in connection with emergence	Additional Paid-In Capital Issuance of new common stock under the Equity Rights Offering	Additional Paid-In Capital Issuance of new common stock for the Equity Rights Offering backstop commitment	Additional Paid-In Capital Issuance of new common stock for Bitmain obligation	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjusted Balance	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjusted Balance
Beginning balance (in shares) at Dec. 31, 2023								386,883					386,883
Beginning balance at Dec. 31, 2023	$ (596,941)					$ 24	$ (596,917)	$ 36					$ 36	$ 1,823,260					$ 1,823,260	$ (2,420,237)	$ 24	$ (2,420,213)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	210,691																			210,691
Stock-based compensation	(1,060)													(1,060)
Cancellation of common stock in connection with emergence (in shares)								(386,883)
Cancellation of common stock in connection with emergence	0							$ (36)						36
Issuance of new common stock (in shares)									152,497	15,649	2,111	10,735
Issuance of new common stock		$ 296,496	$ 55,000	$ 5,475	$ 27,839				$ 2						$ 296,494	$ 55,000	$ 5,475	$ 27,839
Conversion premium on the issuance of the New Secured Convertible Notes	33,202													33,202
Issuance of warrants	(345,856)													(345,856)
Exercise of stock options	9													9
Restricted stock awards issued, net of tax withholding obligations (in shares)								1,285
Restricted stock awards issued, net of tax withholding obligations	(3,388)													(3,388)
Restricted stock awards forfeited (in shares)								(40)
Ending balance (in shares) at Mar. 31, 2024								182,237
Ending balance at Mar. 31, 2024	$ (318,509)							$ 2						1,891,011						(2,209,522)
Beginning balance (in shares) at Dec. 31, 2024	292,606							292,606
Beginning balance at Dec. 31, 2024	$ (943,049)							$ 3						2,915,035						(3,858,087)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	576,251																			576,251
Stock-based compensation	16,405													16,405
Restricted stock awards issued, net of tax withholding obligations (in shares)								2,981
Restricted stock awards issued, net of tax withholding obligations	(50)													(50)
Exercise of warrants (in shares)								3,500
Exercise of warrants	$ 41,625													41,625
Ending balance (in shares) at Mar. 31, 2025	299,087							299,087
Ending balance at Mar. 31, 2025	$ (308,818)							$ 3						$ 2,973,015						$ (3,281,836)